10/8/2025

Janusmed kön och genus

Janusmed kön och genus – Bortezomib Fresenius Kabi

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Bortezomib

Bortezomib

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Velcade (bortezomib). DailyMed [www]. US National Library of Medicine. [updated 2025-08-28, cited 2025-08-17].

  2. Velcade (bortezomib). Summary of Product Charateristics. European Medicines Agency [updated 2024-05-01, cited 2025-08-17]

  3. Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K. Clinical outcomes of bortezomib-based therapy in myeloma. PLoS One. 2018;13(12):e0208920.

  4. Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY et al. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. PLoS One. 2019;14(9):e0222522.

  5. Mauermann M, Dispenzieri A, and Staff N . The Clinical Spectrum of Bortezomib-Induced Peripheral Neuropathy [abstract]. Neurology. 2012;78 (Number 1 supplement).

  6. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31.

  7. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010;21(9):877-81.

  1. Velcade (bortezomib). DailyMed [www]. US National Library of Medicine. [updated 2025-08-28, cited 2025-08-17].
  2. Velcade (bortezomib). Summary of Product Charateristics. European Medicines Agency [updated 2024-05-01, cited 2025-08-17]
  3. Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K. Clinical outcomes of bortezomib-based therapy in myeloma. PLoS One. 2018;13(12):e0208920.
  4. Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY et al. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. PLoS One. 2019;14(9):e0222522.
  5. Mauermann M, Dispenzieri A, and Staff N . The Clinical Spectrum of Bortezomib-Induced Peripheral Neuropathy [abstract]. Neurology. 2012;78 (Number 1 supplement).
  6. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31.
  7. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010;21(9):877-81.